Assenagon Asset Management S.A. Has $30.12 Million Stock Holdings in Align Technology, Inc. $ALGN

Key Points

• Assenagon Asset Management boosted its stake in Align Technology by 54.8%, acquiring 68,299 shares to hold 192,859 shares worth about $30.12 million (≈0.27% of the company) at the quarter end.
• Quarterly results beat estimates: Align reported $3.29 EPS vs. $2.99 expected and $1.05B revenue vs. $1.03B expected, with revenue up 5.3% year-over-year and analysts projecting roughly 7.98 EPS for the fiscal year.
• Market and analyst sentiment is mixed but tilted positive: the consensus rating is a "Moderate Buy" with a target near $198, yet rising short interest (up ~25.5% to ~2.96M shares, ~4.2%) and some downgrades underline execution risks.

Assenagon Asset Management S.A. boosted its position in Align Technology, Inc. (NASDAQ:ALGN - Free Report) by 54.8% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 192,859 shares of the medical equipment provider's stock after buying an additional 68,299 shares during the period. Assenagon Asset Management S.A. owned approximately 0.27% of Align Technology worth $30,115,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Align Technology by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,222 shares of the medical equipment provider's stock valued at $1,624,000 after purchasing an additional 469 shares in the last quarter. Focus Partners Wealth lifted its stake in shares of Align Technology by 5.2% in the first quarter. Focus Partners Wealth now owns 3,062 shares of the medical equipment provider's stock valued at $486,000 after buying an additional 151 shares in the last quarter. Sivia Capital Partners LLC bought a new position in shares of Align Technology in the second quarter valued at $204,000. Cetera Investment Advisers grew its holdings in shares of Align Technology by 4.1% during the second quarter. Cetera Investment Advisers now owns 9,451 shares of the medical equipment provider's stock valued at $1,789,000 after buying an additional 374 shares during the last quarter. Finally, Magnetar Financial LLC acquired a new position in shares of Align Technology during the second quarter valued at about $230,000. Institutional investors own 88.43% of the company's stock.

Key Headlines Impacting Align Technology

Here are the key news stories impacting Align Technology this week:

• Positive Sentiment: Analysts highlight accelerating growth for Align driven by record aligner demand and expansion into dental service organizations (DSOs), arguing ALGN has clearer upside vs. peers. HOLX vs. ALGN: Which MedTech Stock Is the Better Investment Pick Now?
• Positive Sentiment: Brokerage consensus: ALGN was given an average rating of “Moderate Buy,” signaling analyst support that can underpin the share price. Align Technology, Inc. NASDAQ: ALGN Given Average Rating of "Moderate Buy" by Brokerages
• Positive Sentiment: Technical/market signal: Align scored a relative-strength rating upgrade and hit a key benchmark — a momentum signal that can attract trend-following flows. Align Technology scores relative strength rating upgrade; hits key benchmark
• Neutral Sentiment: Analyst fair-value landscape is shifting slightly higher (new fair-value estimates near ~$200), framing the recent pullback as a potential entry point for value-oriented investors; useful for gauging risk/reward but not a guaranteed catalyst. How The Align Technology (ALGN) Story Is Shifting After The Pullback And New US$200 Targets
• Negative Sentiment: Short interest rose meaningfully in March (shorts ~2.96M shares as of Mar 13, up ~25.5% from Feb), representing ~4.2% of shares — increased short activity can pressure the stock if negative headlines persist.
• Negative Sentiment: Critical sell-side view: a recent downgrade argues ALGN needs stronger international growth to justify current valuation, highlighting execution risks and providing a bearish narrative that may weigh on sentiment. Align Technology: Only International Growth Can Save Them Now (Downgrade)

Align Technology Price Performance

Shares of ALGN stock opened at $180.27 on Thursday. The firm has a 50-day moving average of $177.13 and a 200-day moving average of $155.33. Align Technology, Inc. has a one year low of $122.00 and a one year high of $208.30. The company has a market cap of $12.85 billion, a P/E ratio of 31.85, a P/E/G ratio of 1.95 and a beta of 1.79.

Align Technology (NASDAQ:ALGN - Get Free Report) last released its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $3.29 earnings per share for the quarter, topping the consensus estimate of $2.99 by $0.30. Align Technology had a net margin of 10.17% and a return on equity of 15.16%. The business had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.03 billion. During the same period in the previous year, the company earned $2.44 earnings per share. The firm's revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, research analysts expect that Align Technology, Inc. will post 7.98 earnings per share for the current fiscal year.

Insider Buying and Selling at Align Technology

In other news, EVP John Morici sold 7,969 shares of the business's stock in a transaction that occurred on Wednesday, February 18th. The stock was sold at an average price of $189.31, for a total value of $1,508,611.39. Following the transaction, the executive vice president owned 8,237 shares in the company, valued at $1,559,346.47. The trade was a 49.17% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.66% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ALGN shares. Weiss Ratings upgraded shares of Align Technology from a "sell (d+)" rating to a "hold (c-)" rating in a report on Friday, January 16th. UBS Group lifted their price target on Align Technology from $175.00 to $185.00 and gave the company a "neutral" rating in a research note on Thursday, February 5th. Mizuho boosted their price objective on Align Technology from $200.00 to $215.00 and gave the stock an "outperform" rating in a report on Thursday, February 5th. Piper Sandler increased their price objective on Align Technology from $200.00 to $220.00 and gave the stock an "overweight" rating in a research note on Thursday, February 5th. Finally, Wall Street Zen upgraded Align Technology from a "buy" rating to a "strong-buy" rating in a report on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, Align Technology currently has an average rating of "Moderate Buy" and a consensus target price of $198.08.

Align Technology Company Profile

Align Technology, Inc NASDAQ: ALGN pioneered the use of digital technology in orthodontics through the development of the Invisalign system, a series of clear, removable aligners that provide an alternative to traditional metal braces. Since its founding in 1997 by Zia Chishti and Kelsey Wirth, the Tempe, Arizona–based company has expanded its focus to include intraoral scanners, CAD/CAM software for dental laboratories and comprehensive digital dentistry solutions.

The company's signature Invisalign system leverages 3D imaging and computer-aided design (CAD) to create customized aligners that gradually reposition teeth, improving patient comfort and treatment predictability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.